| Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784) |
|---|
| 09/27/2001 | CA2404078A1 Immunokine composition and method |
| 09/27/2001 | CA2404076A1 Heterocyclic side chain containing metalloprotease inhibitors |
| 09/27/2001 | CA2403828A1 Inhibitors of p38 |
| 09/27/2001 | CA2403818A1 Matrices containing nitric oxide donors and reducing agents and their use |
| 09/27/2001 | CA2403815A1 An infective endogenous retrovirus in association with demyelinating diseases e.g. multiple sclerosis |
| 09/27/2001 | CA2403805A1 Amines substituted with a dihydronaphthalenyl, crhomenyl, or thiochromenyl group, an aryl or heteroaryl group and an alkyl group, having retinoid-like biological activity |
| 09/27/2001 | CA2403803A1 Molecule of pharmaceutical interest comprising at its n-terminal a glutamic acid or a glutamine in the form of a physiologically acceptable strong acid |
| 09/27/2001 | CA2403788A1 Receptor-binding compounds and methods for identifying them |
| 09/27/2001 | CA2403784A1 Binding compounds and methods for identifying binding compounds |
| 09/27/2001 | CA2403718A1 A method for generating immunogens that elicit neutralizing antibodies against fusion-active regions of hiv envelope proteins |
| 09/27/2001 | CA2403707A1 Diphenyl ketoaldehyde derivatives with anti-hiv activity |
| 09/27/2001 | CA2403681A1 Therapeutic anti-cytomegalovirus compounds |
| 09/27/2001 | CA2403669A1 Methods and reagents for regulation of cellular responses in biological systems |
| 09/27/2001 | CA2403553A1 Novel amphipathic aldehydes and their use as adjuvants and immunoeffectors |
| 09/27/2001 | CA2403491A1 Use of lactic acid bacterium for the prevention of peritonitis |
| 09/27/2001 | CA2403447A1 Peptide derivative |
| 09/27/2001 | CA2403359A1 Cross-reactive displacing antibodies from collagen-binding proteins and method of identification and use |
| 09/27/2001 | CA2403075A1 Mono- and disaccharides for the treatment of nitric oxide related disorders |
| 09/27/2001 | CA2402763A1 Proteases |
| 09/27/2001 | CA2402747A1 G-protein associated molecules |
| 09/27/2001 | CA2402611A1 Bactericidal preparation |
| 09/27/2001 | CA2402596A1 Anti-tissue factor antibodies with enhanced anticoagulant potency |
| 09/27/2001 | CA2402285A1 Nimr compositions and their methods of use |
| 09/27/2001 | CA2402252A1 Salmonella vaccine materials and methods |
| 09/27/2001 | CA2401908A1 Amorphous torasemide modification |
| 09/27/2001 | CA2401870A1 Cyclic .beta.-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-.alpha. |
| 09/27/2001 | CA2401728A1 Difluorobutyric acid metalloprotease inhibitors |
| 09/27/2001 | CA2401067A1 Methods for screening and identifying pathogen virulence factors |
| 09/27/2001 | CA2400168A1 Beta-amino acid derivatives as inhibitors of matrix metalloproteases and tnf-alpha |
| 09/27/2001 | CA2400118A1 Oxazolidinone tablet formulation |
| 09/27/2001 | CA2400114A1 Container for linezolid intravenous solution |
| 09/27/2001 | CA2400000A1 4-oxo-1,4-dihydro-3-cinnolinecarboxamides as antiviral agents |
| 09/27/2001 | CA2399991A1 4-hydroxy-1,8-naphthyridine-3-carboxamides as antiviral agents |
| 09/27/2001 | CA2399695A1 Pharmaceutical composition for administration to mucosal surfaces |
| 09/27/2001 | CA2389173A1 Agent for treating hepatitis c |
| 09/26/2001 | EP1136571A2 Detection of polymorphisms in the MxA gene to predict the response of an hepatitis C virus infected individual to interferon therapy |
| 09/26/2001 | EP1136562A2 Feline leukemia virus vaccines |
| 09/26/2001 | EP1136500A2 Seroreactive regions from the HPV proteins E1 and E2 |
| 09/26/2001 | EP1136482A1 2-Amino-3-(alkyl)-pyrimidone derivatives as GSK3beta inhibitors |
| 09/26/2001 | EP1136479A1 Oxygenated-heterocycle containing sulfonamide inhibitors of aspartyl protease |
| 09/26/2001 | EP1136075A1 Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| 09/26/2001 | EP1135535A2 Development of anti-microbial agents based on bacteriophage genomics |
| 09/26/2001 | EP1135516A1 Use of an immuno complex for the preparation of a therapeutic composition useful for transfecting a polynucleotide into macropinocyte cells |
| 09/26/2001 | EP1135515A2 Use of trans-activation and cis-activation to modulate the persistence of expression of a transgene |
| 09/26/2001 | EP1135509A2 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 09/26/2001 | EP1135504A2 Human ubiquitin ligase e3 for the modulation of nf-kappa b |
| 09/26/2001 | EP1135503A2 DRUG TARGETS IN $i(CANDIDA ALBICANS) |
| 09/26/2001 | EP1135501A1 Chlamydia antigens and corresponding dna fragments and uses thereof |
| 09/26/2001 | EP1135496A2 Ucp5 |
| 09/26/2001 | EP1135486A1 RECOMBINANT SOLUBLE Fc RECEPTORS |
| 09/26/2001 | EP1135484A2 Gtpase associated proteins |
| 09/26/2001 | EP1135481A1 New oligomeric conjugates liable to transfer biological molecules into cells |
| 09/26/2001 | EP1135468A1 Virus vectors and methods of making and administering the same |
| 09/26/2001 | EP1135439A1 Poly(alpha-1,4-d-glucan) and thermoplastic polymer mixtures containing the same |
| 09/26/2001 | EP1135411A1 Methods and compositions for treating disorders involving excitotoxicity |
| 09/26/2001 | EP1135401A1 Glyceryl nucleotides, method for the production thereof and their use |
| 09/26/2001 | EP1135400A1 Hygromycin a derivatives as antibacterial agents |
| 09/26/2001 | EP1135395A1 Crystalline salts of a carbapenem antibiotic |
| 09/26/2001 | EP1135164A1 Method for the treatment of inflammation |
| 09/26/2001 | EP1135163A1 Topical compositions comprising ascomycins |
| 09/26/2001 | EP1135162A2 Ordered molecular presentation of antigens, method of preparation and use |
| 09/26/2001 | EP1135161A1 Chemotherapeutic composition and method |
| 09/26/2001 | EP1135159A2 Peptide-based vaccine for influenza |
| 09/26/2001 | EP1135158A2 Enhanced vaccines |
| 09/26/2001 | EP1135152A1 A pharmaceutical composition comprising cyclosporin in a lipid carrier |
| 09/26/2001 | EP1135151A1 Peptoid and nonpeptoid containing alpha-keto oxadiazoles as serine protease inhibitors |
| 09/26/2001 | EP1135144A1 Compositions and methods for regulating bacterial pathogenesis |
| 09/26/2001 | EP1135138A2 Use of 17-ketosteroids for the treatment of malaria and trypanosomiasis |
| 09/26/2001 | EP1135137A1 Copolymer compositions for treating viral infections |
| 09/26/2001 | EP1135136A1 Pharmaceutical compositions containing olanzapine-n-oxide |
| 09/26/2001 | EP1135132A2 Inhibitors of multidrug transporters |
| 09/26/2001 | EP1135131A1 Aryl and heterocyclyl substituted pyrimidine derivatives as anti-coagulants |
| 09/26/2001 | EP1135115A2 Use of sibutramine for the treatment of disorders of the central nervous system secondary to organic impairments |
| 09/26/2001 | EP1135112A1 An oral formulation for gastrointestinal drug delivery |
| 09/26/2001 | EP1135111A2 Autoadhesive oral transmucosal delivery dosage form |
| 09/26/2001 | EP1135105A2 Method for administering agents to the central nervous system |
| 09/26/2001 | EP1135025A1 Plasmid maintenance system for antigen delivery |
| 09/26/2001 | EP1031570A4 Immuno-modulator exhibiting anti-microbial and anti-mycobacterial activities, method for producing the same and pharmaceutical preparation for treating mycobacterioses as well as lung chronic and non specific conditions, sexually transmitted diseases and the resulting immuno-deficiency |
| 09/26/2001 | EP0839026B1 Polyether block copolymer micellar compositions for targeting biological agents |
| 09/26/2001 | EP0833825B1 6-carboxamido dihydropyran derivatives |
| 09/26/2001 | EP0825860B1 Use of a composition comprising amoxycillin and clavulanic acid for the manufacture of a medicament for the treatment of bacterial infections in paediatric patients |
| 09/26/2001 | EP0809653B1 Helicobacter pylori antigen |
| 09/26/2001 | EP0805685B1 Novel antifungal cyclohexapeptides |
| 09/26/2001 | EP0804581B1 Compounds and methods for the stimulation and enhancement of protective immune responses and il-12 production |
| 09/26/2001 | EP0773943B1 Compounds useful as antiproliferative agents and garft inhibitors |
| 09/26/2001 | EP0767796B1 Chemotactic protein |
| 09/26/2001 | EP0707591B1 Methylphosphonic acid ester, process for preparing the same and its use |
| 09/26/2001 | CN1314953A Method and compositions to identify swine genetically resistant to F18 E. coli associated diseases |
| 09/26/2001 | CN1314948A Targeted adenovirus vectors for delivery of heterologous genes |
| 09/26/2001 | CN1314942A Newcastle disease virus infection clones, vaccine and diagnostic assays |
| 09/26/2001 | CN1314940A Temperature-sensitive and cold-adapted human parainfluenza virus type 2(HPIV-2) and vaccines based on such virus |
| 09/26/2001 | CN1314909A Aryl phosphate derivatives of d4T having anti-HIV activity |
| 09/26/2001 | CN1314893A IL-8 receptor antanonists |
| 09/26/2001 | CN1314813A Novel isoxazolinone antibacterial agent |
| 09/26/2001 | CN1314809A Method of vaccination of newly hatched poultry |
| 09/26/2001 | CN1314349A Metronizole succinic acid monoester sodium and potassium salt and preparing method and use |
| 09/26/2001 | CN1314347A Six kinds of isoquinoline alkaloid |
| 09/26/2001 | CN1314169A Medicine for treating hepatitis B |
| 09/26/2001 | CN1314155A Mampalon perfume and its producing method |
| 09/26/2001 | CN1071760C N-terminally chemically modified protein composition and methods |